Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

A Houston-based compounding pharmacy has fired back against a lawsuit filed by the pharmaceutical giant that makes Mounjaro ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

Hims & Hers Health Inc. shares slid over 2.8% on Tuesday and continued declining after-hours trading after Eli Lilly ...

Results from a first-in-human Phase Ia/Ib trial show that LY4170156 demonstrated a notably high overall response rate in ...

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the ...

Madison Investments, an investment advisor, released its “Madison Sustainable Equity Strategy” first quarter 2025 investor ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...